ArticleJAMA network open2025
Cannabinoid Hyperemesis Syndrome, 2016 to 2022.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Trends in Emergency Department Visits Involving Cannabis Hyperemesis Syndrome Identified Using a New Diagnosis Code - United States, January 2023-May 2026.MMWR. Morbidity and mortality weekly report · 2026Article
- Links between Cannabinoid Hyperemesis Syndrome symptoms and drug use, mental health problems, antisocial behavior, and personality in a national survey of adults in the United States.medRxiv : the preprint server for health sciences · 2026Article
- Suspected Cannabinoid Hyperemesis Syndrome in a Traveler from a Cannabis-Legal Country: A Case Report from Japan.Juntendo medical journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Cannabinoid hyperemesis syndrome (CHS), ie, recurrent emesis from chronic cannabis use, is increasingly observed in emergency departments (EDs), yet population-level estimates and sociodemographic correlates remain underexplored. Objective: To estimate CHS prevalence in US EDs, assess trends from 2016 to 2022, and examine sociodemographic associations. Design, Setting, and Participants: This cross-sectional study, using data from the Nationwide Emergency Department Sample (approximately 85% of annual US ED visits) examined patients aged 12 years and older. Patients with ED visits related to pregnancy, gastroparesis, or chemotherapy were excluded. Main Outcomes and Measures: ED visits were grouped into 4 categories. Primary outcome was comparative temporal trends between each of the 4 categories: (1) no cannabis use or cyclic vomiting syndrome (CVS); (2) cannabis-related condition only; (3) CVS only; and (4) both cannabis-related condition and CVS (CHS proxy). Restricted cubic splines modeled temporal trends; multinomial logistic regression identified sociodemographic factors associated with CHS. Results: The analytic sample included 188 610 906 unweighted visits (806 million weighted); 433 251 323 (54.4%) were female; mean (SD) age, 47.9 years (95% CI, 47.8-48.1 years). CHS increased from 4.4 per 100 000 visits, peaked at 33.1 in quarter 2 2020, and remained elevated at 22.3 in 2022; concurrently, CVS-only declined from 300 to 186 per 100 000 visits. Females had lower CHS risk (RRR, 0.92; 95% CI, 0.88-0.95) as did patients in the South vs Northeast (RRR, 0.46; 95% CI, 0.40-0.53); risk was highest at ages 18 to 25 years (RRR, 3.59; 95% CI, 3.38-3.81) and 26 to 35 years (RRR, 2.26; 95% CI, 2.14-2.40). Conclusions And Relevance: In this cross-sectional study of US ED visits, CHS prevalence increased sharply during the COVID-19 pandemic and remained elevated. The findings highlight the need for continued vigilance and refinements to the clinical recognition of CHS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.